News

Medison Pharma’s Amvuttra (vutrisiran) has entered Korea’s reimbursement system for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), raising…

AbstractAcute heart failure (AHF) represents a major global health challenge, with a substantial impact on survival, morbidity, and health care resource utilization…

AbstractBACKGROUND:Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-…

AbstractBackground and ObjectiveWe assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across…

There were no safety findings associated with vitamin A deficiency following treatment with patisiran or vutrisiran in patients with transthyretin (TTR) amyloidosis…

AbstractSystemic amyloid light-chain (AL) amyloidosis is a multisystem disorder caused by extracellular deposition of monoclonal immunoglobulin light chains.…

AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…

AbstractBackgroundPathogenic transthyretin (TTR) variants, such as V142I, demonstrate incomplete, age-dependent penetrance and may be present in patients without…

AbstractTransthyretin amyloidosis (ATTR) is a rare, progressive, and fre- quently under-recognized systemic disease whose early clinical manifes- tations may…

Prothena Biosciences announced that coramitug (previously PRX004) has received Fast Track designation for the treatment of transthyretin amyloid cardiomyopathy…